Chancen auf Heilung sind besser denn je

[1]  H. Tietz.  Keine Lokalbehandlung ohne sporoziden Wirkstoff , 2017, hautnah dermatologie.

[2]  E. Debus,et al.  Therapie der pAVK - Wann wird´s kritisch? , 2017 .

[3]  M. Jünger,et al.  Treating onychomycosis with the short‐pulsed 1064‐nm‐Nd:YAG laser: results of a prospective randomized controlled trial , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  P. Mayser.  [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions]. , 2016, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[5]  M. Schaller,et al.  Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections , 2015, Mycoses.

[6]  R. Upton,et al.  Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States , 2015, Antimicrobial Agents and Chemotherapy.

[7]  L. Christiansen,et al.  Pharmacokinetic-Pharmacodynamic Model To Evaluate Intramuscular Tetracycline Treatment Protocols To Prevent Antimicrobial Resistance in Pigs , 2014, Antimicrobial Agents and Chemotherapy.

[8]  Yuquan Wei,et al.  Itraconazole suppresses the growth of glioblastoma through induction of autophagy , 2014, Autophagy.

[9]  V. Fabrizi,et al.  Skin and nail mycoses in patients with diabetic foot. , 2013, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[10]  R. Hay,et al.  Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: a double‐blind, randomized, placebo‐controlled multicenter study , 2013, Mycoses.

[11]  F. Pankewitz,et al.  Development of a novel polymerase chain reaction–enzyme‐linked immunosorbent assay for the diagnosis of Trichophyton rubrum onychomycosis , 2013, The British journal of dermatology.

[12]  W. Bäumler,et al.  Laser treatment of onychomycosis: an in vitro pilot study , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  P. Nenoff,et al.  Onychomykose – ein Update , 2011, Der Hautarzt.

[14]  A. Tosti,et al.  An innovative water‐soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  J. Szepietowski,et al.  Stigmatisation in onychomycosis patients: a population‐based study , 2009, Mycoses.

[16]  W. Weger,et al.  Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  G. Mcinnes,et al.  Exforge: ARB/CCB combination for better hypertension control , 2007 .

[18]  B. Elewski,et al.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality , 2005, Therapeutics and clinical risk management.

[19]  El Fari,et al.  Development of an oligonucleotide probe specific for Trichophytonrubrum , 1999, The British journal of dermatology.

[20]  B. Sigurgeirsson,et al.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .

[21]  M. Gold,et al.  Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. , 1988, Journal of the American Academy of Dermatology.

[22]  S. Tyagi,et al.  A strain of Trichophyton rubrum endemic to Nigeria. , 1964, Sabouraudia.